Neurologic Phenotype of Schimke Immuno-Osseous Dysplasia and Neurodevelopmental Expression of SMARCAL1

Kimiko Deguchi, MD, PhD, Johanna M. Clewing, MD, Leah I. Elizondo, Ryuki Hirano, MD, PhD, Cheng Huang, MD, PhD, Kunho Choi, MS, Emily A. Sloan, Thomas Lücke, MD, Katja M. Marwedel, MD, Ralph D. Powell Jr, MD, Karen Santa Cruz, MD, Sandrine Willaime-Moraweck, PhD, Ken Inoue, MD, PhD, Shu Lou, MD, Jennifer L. Northrop, MD, PhD, Yonehiro Kanemura, MD, PhD, Derek van der Kooy, PhD, Hideyuki Okano, MD, PhD, Dawna L. Armstrong, MD, and Cornelius F. Boerkoel, MD, PhD

Abstract

Schimke immuno-osseous dysplasia (OMIM 242900) is an uncommon autosomal-recessive multisystem disease caused by mutations in SMARCAL1 (swi/swr-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1), a gene encoding a putative chromatin remodeling protein. Neurologic manifestations identified to date relate to enhanced atherosclerosis and cerebrovascular disease. Based on a clinical survey, we determined that half of Schimke immuno-osseous dysplasia patients have a small head circumference, and 15% have social, language, motor, or cognitive abnormalities. Postmortem examination of 2 Schimke immuno-osseous dysplasia patients showed low brain weights and subtle brain histologic abnormalities suggestive of perturbed neuron-glial migration such as heterotopia, irregular cortical thickness, incomplete gyral formation, and poor definition of cortical layers. We found that SMARCAL1 is highly expressed in the developing and adult mouse and human brain, including neural precursors and neuronal lineage cells. These observations suggest that SMARCAL1 deficiency may influence brain development and function in addition to its previously recognized effect on cerebral circulation.

Key Words: Immunodeficiency, Microcephaly, Neural stem cell, Neuronal migration, Renal disease, Skeletal dysplasia

INTRODUCTION

Neurons of the central nervous system (CNS) originate from the neural precursors within the neuroepithelium surrounding the developing ventricles. The neuronal or glial destiny of the precursors is partly dependent on the number of preceding cell cycles (1). Neurons arise more frequently when the precursor has completed fewer cell divisions, whereas glia arise more frequently when the precursor has completed a higher number of cell divisions (2, 3). Additionally, symmetric or asymmetric cell division determines whether both progeny of a neural precursor remain precursors or whether 1 daughter cell will become a neuron or glia and 1 daughter cell will remain as a neural precursor (2, 4).

The migration of neuronal precursors from the neuroepithelium is carefully choreographed to form cortical layers 2 to 6 (5). A major population of neuronal precursors is guided to the cortex by climbing radial glial fibers (6). The cerebral cortex is formed by an inside-out migration; thus, neurons generated early in cortical development occupy more proximal or internal layers, and those generated later occupy more distal or external layers (7). Neuronal migration can be divided into several key stages according to mutations identified in human diseases: initiation of migration, effective migration, and penetration of the subplate (8).
Schimke immuno-osseous dysplasia (SIOD; OMIM 242900) is an uncommon autosomal-recessive multisystem disease caused by mutations in the putative chromatin remodeling protein SMARCAL1 (swi/snf-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1). Clinical studies of SIOD have suggested that this multisystem disease is the result of a defect in selective cellular proliferation because its phenotype includes short stature from impaired chondrogenesis, T-cell deficiency from impaired T-cell proliferation, azoospermia from testicular hypoplasia, and, occasionally, bone marrow failure from impaired blood precursor proliferation (9, 10). Other aspects of SIOD are also consistent with impaired differentiation and tissue maintenance and include progressive atherosclerosis leading to cerebral ischemic lesions, renal failure from focal segmental glomerulosclerosis, and fatty infiltration of the right ventricular wall resembling an arrhythmogenic right ventricular cardiomyopathy (9, 10). SMARCAL1 is homologous to the SNF2 chromatin remodeling proteins and the SF2 family of helicases (11, 12). In vitro, SMARCAL1 has DNA-dependent adenosine triphosphatase activity and binds nucleosomes (12, 13), but its in vivo function has not been defined.

In this study, we investigated possible roles of SMARCAL1 in CNS development by characterizing nonischemic brain pathology in autopsy tissue from 2 patients with SIOD. Both patients had a reduced brain weight and subtle microscopic findings suggestive of malformative processes. To explore the possible implications of these developmental brain lesions, we examined the records of 33 SIOD patients with SMARCAL1 mutations for evidence of decreased brain size, psychomotor delay, and seizures. We found that nearly half of SIOD patients had a head circumference at least 2 standard deviations less than the mean, and approximately 15% had social, language, motor, or cognitive abnormalities. To determine whether these functional and morphologic problems might correlate with disordered brain development in SIOD, we analyzed SMARCAL1 expression in human and murine neural development. SMARCAL1 was found to be highly expressed in human and mouse neural precursors and neurons. Thus, the loss of functional SMARCAL1 may affect the regulation of brain development and cause cerebrovascular ischemia in SIOD.

**MATERIALS AND METHODS**

**Human Subjects**

Patients referred to this study gave informed consent approved by the institutional review board of Baylor College of Medicine (Houston, TX) or the Hospital for Sick Children (Toronto, Ontario, Canada). The clinical data for patients were obtained from questionnaires completed by the responsible physician and from medical records and summaries provided by that physician. Postmortem tissue samples were obtained from patients whose families gave informed consent approved by the institutional review board of Baylor College of Medicine.

Human brain tissue for Western and Northern analyses was obtained from the Birth Defects Laboratory (University of Washington, Seattle, WA). Human brain tissue for immunohistochemical and immunofluorescent analyses was obtained from autopsy specimens of unaffected individuals aged 6 gestational weeks (GW) to 61 years; these were obtained after informed consent approved by the institutional review board of Baylor College of Medicine and Texas Children’s Hospital. The autopsies were performed within 24 hours of death.

**Tissue Pathology and Expression Analyses**

Two to 4 investigators who were blinded to the source of the tissue samples determined the pathologic findings, identified immunohistochemically positive cells, and scored the numbers of immunohistochemically positive cells. The assessments of human tissue were done in both SIOD patients and in human control samples as described in the Results section. The assessment of Smc1 expression in mouse tissue was done using animals of 3 different genetic backgrounds: 129SvEv, C57BL6, and ICR.

**Human and Mouse Neurosphere Culture**

All experiments using human neural precursor cells that were derived from human fetal neural tissue aged 7 to 10 GW were performed at Keio University with the approval of the institutional review board and in agreement with the ethical guidelines of the ethical committees of Osaka National Hospital and Keio University. Tissue procurement was in accordance with the Declaration of Helsinki and in agreement with the ethical guidelines of the Japan Society of Obstetrics and Gynecology.

**Human Neurosphere Culture**

Human neural precursor cell cultures were established using the neurosphere method (14). The cells used had been cultured for more than 1 year. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)/F12 serum-free medium supplemented with B27 supplement (Gibco, Grand Island, NY), recombinant human basic fibroblast growth factor (20 ng/ml; R&D, Minneapolis, MN), recombinant human fibroblast growth factor (20 ng/ml; Genzyme TECHINE, Minneapolis, MN), leukemia inhibiting factor (Chemicon, Temecula, CA), and heparin (Sigma, St. Louis, MO). For differentiation, the cells were dissociated with 0.05% trypsin (Gibco) for 20 minutes at 37°C and plated on polyornithine- and laminin-coated glass coverslips (Sigma), followed by incubation with DMEM/F12 medium with either B27 supplement or 10% fetal bovine serum for 6 days.

**Mouse Neurosphere Culture**

Murine neural precursor cells were established from E12.5 and E14.5 ICR embryos using the neurosphere method (15). Briefly, embryos were removed from the uterus of timed pregnant mice and placed in a Petri dish containing Hank’s balanced salt solution (Gibco). The mouse telencephalon was freed from meninges, and the cells were dissociated by mechanical trituration with a fine narrowed Pasteur pipette. After centrifugation at 800 rpm for 3 minutes, the cells were resuspended in the same culture medium used for human neurosphere culture (but without leukemia inhibiting factor and heparin) and cultured in a humidified atmosphere of 5% CO2 incubator at 37°C. Half of the
medium was changed every 3 days. Primary neurospheres were cultivated for 6 to 10 days before harvest.

For differentiation, 5 to 10 neurospheres were attached onto polyornithine- and laminin-coated glass coverslips (14-mm diameter) in a 24-well plate (Nunc, Roskilde, Denmark) and cultured up to 14 days with DMEM/F12 medium containing either B27 supplement or 10% fetal bovine serum.

**Anti-SMARCAL1 Antibody Production**

An anti-SMARCAL1 antiserum was generated as previously described (16). The antiserum identifies a specific antigen that is not present in patients with biallelic nonsense mutations of SMARCAL1. It recognizes a specific band of the appropriate molecular weight on Western blots of human tissue extracts.

**Western Blotting**

The fetal human brain samples were removed at autopsy, snap-frozen in liquid nitrogen, and stored at −80°C; the adult human brain samples were purchased from BD Biosciences (Franklin Lakes, NJ). Tissues were homogenized in 2× sodium dodecyl sulfate (SDS) sample buffer (Invitrogen, Carlsbad, CA) and boiled for 5 minutes. Protein (10 μg) was loaded into each well, fractionated on a 7% SDS-polyacrylamide gel and electrophoresis gel, and transferred to a polyvinylidene fluoride membrane (Invitrogen). After blocking with phosphate-buffered saline (PBS) containing 0.2% I-Block (Applied Biosystems, Foster City, CA). Tissues were homogenized in 2× SDS-sample buffer (Invitrogen, Carlsbad, CA) and boiled for 5 minutes. Protein (10 μg) was loaded into each well, fractionated on a 7% SDS-polyacrylamide gel, and transferred to a polyvinylidene fluoride membrane (Invitrogen). After blocking with phosphate-buffered saline (PBS) containing 0.2% I-Block (Applie Biosystems, Foster City, CA) for 1 hour at room temperature (RT), a 1:5000 dilution of the anti-SMARCAL1 rabbit polyclonal antibody and a 1:5000 dilution of anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mouse monoclonal antibody (MAB374; Chemicon) were incubated with the membrane for 1 hour at RT. After incubation with the primary antibodies, the Western blots were washed with blocking buffer 3 times for 10 minutes each at RT and then incubated with alkaline phosphatase-conjugated secondary antibodies (anti-rabbit immunoglobulin (IgG) and anti-mouse IgG: A2556 and A3562, respectively; Sigma) for 30 minutes at RT. The blot was then washed 3 times for 10 minutes each at RT. The bound antibody was detected by chemiluminescence using CDP-Star (Applied Biosystems) according to the manufacturer’s specifications.

**Immunohistochemistry**

Human and mouse brain samples were fixed in 10% buffered formalin or 4% paraformaldehyde (PFA) in PBS. The brain tissue was processed, embedded in paraffin, and cut into 8-μm sections according to standard protocols (17). Immunohistochemistry was performed as previously described (16). We used the following primary antibodies: polyclonal rabbit anti-human SMARCAL1 (BCM312), diluted 1:200; monoclonal mouse anti-rat Musashi1 (14H1 [18]), diluted 1:500; anti-human Hu (18), diluted 1:1000; and a polyclonal anti-glial fibrillary acidic protein (GFAP; Dako, Carpinteria, CA), diluted 1:1000.

**Immunofluorescence**

To determine the cell types in which SMARCAL1 was expressed in the human and the mouse brain, we performed double immunofluorescence using a 27-GW human brain and mouse brains ranging in age from E8.5 to adult. The brains were fixed in 4% PFA for 48 hours, immersed in 30% sucrose for 48 hours, and then frozen in optimal cutting temperature-embedding medium on dry ice. After cutting 8- to 20-μm-thick sections using a cryostat, the tissue sections were placed on Superfrost plus microslides (VWR International, West Chester, PA) and incubated with the primary antibodies in 10% normal horse serum for 2 hours at RT or overnight at 4°C. The sections were then rinsed with PBS with 0.02% Tween. For visualization, we used the Alexa 568-conjugated secondary antibodies anti-rat IgG, anti-rabbit IgG, and anti-human IgG, and the Alexa 488-conjugated secondary antibodies anti-rat IgG, anti-rabbit IgG, and anti-human IgG (Molecular Probes, Eugene, OR). After incubation with the secondary antibodies for 30 minutes at RT, the tissue sections were rinsed 4 times with PBS with 0.02% Tween and mounted in Vectashield (Vector Laboratories, Burlingame, CA).

**Reverse-Transcriptase-Polymerase Chain Reaction**

Total RNA was extracted from 2 independent human neural stem cell cultures using the RNAsesy kit (Qiagen). The RNA was reverse transcribed into cDNA using random primers and RNase H-MMLV reverse transcriptase (Stratagene). Primers specific to the human SMARCAL1 cDNA were designed and used for polymerase chain reaction (PCR) amplification (30 cycles of 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute). Amplification of actin cDNAs was used as a reference control. The primer pairs used were 5’-CAGGACCTTATTTGCGCTTTT-3’ and 5’-CGGGACCTTATTTGCGCTTTT-3’ for human SMARCAL1 PCR and 5’-GCTCACCATTGGATGATATCGC-3’ and 5’-GGAGGAGCAATGATCTTGTAC-3’ for actin. The PCR products were run on a 2% agarose gel and detected by ethidium bromide.

**Northern Blot Analysis**

Human tissue Northern blots were purchased from Clontech (Mountain View, CA) and hybridized according to the manufacturer’s instructions. Mouse brains (E14.5 adult)
or heads (E9.5–E12.5) were dissected and snap-frozen in liquid nitrogen. Total RNA was prepared using the Ambion total RNA kit (Ambion, Austin, TX). Total RNA (20 µg) of each sample was loaded onto 1% agarose-formaldehyde gel and transferred to a nylon membrane (Ambion) overnight by capillary transfer using 20 × sodium chloride-sodium citrate (SSC). After prehybridization in hybridization buffer (15% formamide, 40 mM/L of NaPO₄, pH 7.2, 10 mM/L of EDTA, 7% SDS, 2% bovine serum albumin), the filters were hybridized with 3²P-labeled cDNA probes in fresh buffer at 65°C overnight. DNA probes for Northern hybridization were synthesized from the human or the mouse 5'-untranslated region of the SMARCAL1/Smarcal1 cDNA using a random-priming labeling system (Amersham, Piscataway, NJ). Hybridized membranes were washed in buffer (40 mM/L of NaPO₄, 1 mM/L of EDTA, 1% SDS) 3 times for 30 minutes each at 65°C and exposed to film. As a control for the amount of RNA loaded in each lane, the probe was stripped from the membrane with 10 mM/L of Tris-HCl, 1 mM/L of EDTA, 0.1% SDS containing buffer at 100°C, and the membrane was rehybridized with a glyceraldehyde 3-phosphate dehydrogenase probe.

**In Situ Hybridization**

Digoxigenin-labeled mouse Smarcal1 antisense and sense riboprobes were synthesized using an in vitro transcription kit (Roche, Indianapolis, IN) according the instructions. The fresh brain sections were sectioned at 10 µm. Sections were fixed in 4% PFA for 20 minutes and washed twice in 1× PBS, treated with 0.1 N of HCl for 20 minutes, digested with proteinase K in 1× TE at 37°C for 10 minutes, washed once in deionized water, postfixed with 4% PFA for 20 minutes, then incubated in 0.25% acetic anhydride/0.1 mol/L of triethanolamine (pH 8.0) for 10 minutes. After a brief wash with 2× SSC, the sections were prehybridized for 1 hour at 55°C in the hybridization buffer containing 50% deionized formamide, 0.2% SDS, 0.75 mol/L of NaCl, 25 mM/L of piperazine diethanesulfonic acid, 25 mM/L of Tris-HCl and EDTA, 1× Denhardt and 50 µg/ml of salmon sperm DNA, and hybridized in the same buffer containing 1 µg/ml of either antisense or sense Smarcal1 probe at 55°C overnight. After hybridization, the sections were rinsed briefly in 4× SSC at 55°C 5 times for each 5 minutes and 2× SSC for 30 minutes at 55°C. After a 10-minute wash with RNase buffer containing 10 mM/L of Tris-HCl and 0.5 mol/L of NaCl, the unbound RNA probes were digested with 20 µg/ml of RNase A in the same buffer for 30 minutes at 37°C. The sections were then washed 2 times in 0.1× SSC for 15 minutes at RT. After several rinses in Tris-buffered saline (0.15 mol/L of NaCl, 0.1 mol/L of Tris, pH 7.5), the sections were incubated in 0.5% blocking solution (Roche) for 30 minutes at RT, followed by incubation for 2 hours with alkaline phosphatase-conjugated sheep anti-digoxigenin antibody (1:1000; Roche) at RT. After several washes with 50 mM/L of MgCl₂ in Tris-buffered saline, pH 9.5, the phosphatase reaction was performed using nitroblue tetrazolium-5-bromo-4-chloro-3-indolylphosphate as substrates. The color reaction was developed in the dark until satisfying results were obtained.

**RESULTS**

**Neurodevelopment of SIOD Patients**

To ascertain whether SIOD patients have neurologic abnormalities, we sent questionnaires to the physicians of 38 SIOD patients with identified SMARCAL1 mutations and received 33 responses (Table 1). Half of the patients had a head circumference less than the third percentile. We did not detect a significant correlation of head circumference with disease severity as scored using our previously defined scale (19) or with age at death (Figs. 1A, B). Stature was neither predictive of head circumference nor was the head circumference always disproportionately larger or smaller (Fig. 1C); nearly half had disproportionately large or small heads, and of these, half were larger and half were smaller. To date, imaging studies have not identified structural abnormalities indicating a cause of abnormal head growth (16).

We also compared head circumference to the different patient mutations to determine whether the SMARCAL1 mutations were predictive of head circumference. Among patients with a sequence variant encoding a nonsense, frameshift, or deletion mutation on both alleles, 60% had a head circumference less than the third percentile; among patients with a sequence variant encoding a nonsense, frameshift, or deletion mutation on 1 allele and a sequence variant encoding a missense mutation on the other allele, 57% had a head circumference less than the third percentile; and among patients with sequence variants encoding missense mutations on both alleles, 44% had a head circumference less than the third percentile (Fig. 1D). These observations suggest a trend toward preserved brain growth in the background of biallelic missense mutations, but the number of patients is too small for this to be statistically significant.

As assessed by their primary care physicians, 5 of the 33 patients had mild delay of 1 or more developmental parameter; only 1 patient (Patient 57), who had a stroke at 4 years of age, had warranted formal developmental testing and required intervention services (20). Of the 26 patients who attended school, 22 had normal school performance. All patients with a disproportionately large head circumference (Patients 16, 28, 30, 33a, 39, 44, 47, and 51) had normal development, whereas 1 (Patient 27) of 6 patients (Patients 23, 27, 45, 49, 60, and 71) with a disproportionately small head circumference did not. The mutation type was not predictive of a disproportionately small or large head size or of the developmental pattern. Several patients had electroencephalographic (EEG) abnormalities such as excessive background slowing and foci of rhythmic and arrhythmic slowing, but only 2 patients manifested clinical seizures prior to the onset of cerebral ischemia (Table 1).

**SMARCAL1 Expression During Human and Mouse CNS Development**

The findings of frequent microcephaly and EEG abnormalities among SIOD patients prior to their manifestation of cerebral ischemia suggested that SMARCAL1 may play an autonomous role in neurodevelopment. Therefore, we...
### TABLE 1. Clinical Features of 33 Patients with SIOD and SMARCAL1 Mutations

<table>
<thead>
<tr>
<th>Patient (mutation)</th>
<th>OFC Percentile</th>
<th>Height Percentile</th>
<th>Disease Severity Score* (maximum = 5)</th>
<th>Delay</th>
<th>Physician’s Assessment of Developmental Delay</th>
<th>School Performance</th>
<th>EEG Abnormality</th>
<th>Memory Problem</th>
<th>Mood Problem</th>
<th>Age, years</th>
<th>Survival *&lt; 20 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>33a (c.1146_1147delAA+)</td>
<td>3–10</td>
<td>&lt;3</td>
<td>3</td>
<td>No</td>
<td>N/A</td>
<td>UA</td>
<td>UA</td>
<td></td>
<td></td>
<td>2.75</td>
<td>31</td>
</tr>
<tr>
<td>50 (c.2542G&gt;T)</td>
<td>&lt;3</td>
<td>&lt;3</td>
<td>3</td>
<td>No</td>
<td>Normal</td>
<td>Yes†</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>8</td>
<td>11</td>
</tr>
<tr>
<td>53 (c.2291G&gt;A, c.2542G&gt;T)</td>
<td>50</td>
<td>50</td>
<td>3</td>
<td>No</td>
<td>Normal</td>
<td>UA</td>
<td>UA</td>
<td></td>
<td></td>
<td>13.5</td>
<td>38</td>
</tr>
<tr>
<td>8 (c.1190delT)</td>
<td>&lt;3</td>
<td>&lt;3</td>
<td>4</td>
<td>No</td>
<td>N/A</td>
<td>UA</td>
<td>UA</td>
<td></td>
<td></td>
<td>5.7</td>
<td>9</td>
</tr>
<tr>
<td>23 (c.2542G&gt;T)</td>
<td>&lt;3</td>
<td>3–10</td>
<td>4</td>
<td>No</td>
<td>N/A</td>
<td>UA</td>
<td>UA</td>
<td></td>
<td></td>
<td>10.25</td>
<td>16</td>
</tr>
<tr>
<td>28 (c.1702delG)</td>
<td>50</td>
<td>3–10</td>
<td>4</td>
<td>No</td>
<td>Normal</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td></td>
<td>12</td>
<td>17</td>
</tr>
<tr>
<td>31 (Del ex1-4)</td>
<td>&lt;3</td>
<td>&lt;3</td>
<td>4</td>
<td>No</td>
<td>Normal</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td></td>
<td>14</td>
<td>15</td>
</tr>
<tr>
<td>35 (c.1736C&gt;T, c.2323C&gt;A)</td>
<td>&lt;3+</td>
<td>&lt;3</td>
<td>4</td>
<td>No</td>
<td>Normal</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td></td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>47 (c.2545G&gt;A)</td>
<td>25–50</td>
<td>&lt;3</td>
<td>4</td>
<td>No</td>
<td>Normal</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td></td>
<td>16.6</td>
<td>43</td>
</tr>
<tr>
<td>48 (c.1939A&gt;C)</td>
<td>&lt;3</td>
<td>3</td>
<td>4</td>
<td>Yes</td>
<td>Mild delay</td>
<td>Normal</td>
<td>No</td>
<td></td>
<td></td>
<td>6</td>
<td>25</td>
</tr>
<tr>
<td>49 (c.1920_1921insG)</td>
<td>&lt;3</td>
<td>10</td>
<td>4</td>
<td>No</td>
<td>Normal</td>
<td>UA</td>
<td>UA</td>
<td></td>
<td></td>
<td>4.8</td>
<td>42</td>
</tr>
<tr>
<td>60 (c.2542G&gt;T)</td>
<td>&lt;3</td>
<td>25</td>
<td>4</td>
<td>No</td>
<td>Normal</td>
<td>No</td>
<td>No</td>
<td>13.6</td>
<td></td>
<td>11</td>
<td>18</td>
</tr>
<tr>
<td>61 (c.1146_1147delAA+)</td>
<td>UA</td>
<td>&lt;3</td>
<td>4</td>
<td>No</td>
<td>N/A</td>
<td>No</td>
<td>No</td>
<td>5</td>
<td></td>
<td>13</td>
<td>7</td>
</tr>
<tr>
<td>66 (c.1933C&gt;T)</td>
<td>&lt;3+</td>
<td>&lt;3+</td>
<td>4</td>
<td>No</td>
<td>Normal</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td></td>
<td>13</td>
<td>4</td>
</tr>
<tr>
<td>68 (c.1940A&gt;C, c.2462T&gt;G)</td>
<td>3–10</td>
<td>3–10</td>
<td>4</td>
<td>No</td>
<td>Normal</td>
<td>Yes</td>
<td>No</td>
<td></td>
<td></td>
<td>7.1</td>
<td>22</td>
</tr>
<tr>
<td>72 (c.836C&gt;T, c.1136A&gt;C)</td>
<td>&lt;3</td>
<td>&lt;3</td>
<td>4</td>
<td>No</td>
<td>Normal</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
<td>9.6</td>
<td>6</td>
</tr>
<tr>
<td>74 (c.1736C&gt;T)</td>
<td>10–25</td>
<td>10–25</td>
<td>4</td>
<td>No</td>
<td>N/A</td>
<td>No</td>
<td>No</td>
<td>7.5</td>
<td></td>
<td>11</td>
<td>20</td>
</tr>
<tr>
<td>24 (Del ex1-4)</td>
<td>&lt;3†</td>
<td>&lt;3†</td>
<td>5</td>
<td>Yes</td>
<td>Mild delay</td>
<td>Normal</td>
<td>No</td>
<td></td>
<td></td>
<td>9</td>
<td>14</td>
</tr>
<tr>
<td>25 (c.49C&gt;T, c.100C&gt;T)</td>
<td>50+</td>
<td>UA</td>
<td>5</td>
<td>No</td>
<td>Normal</td>
<td>Yes†</td>
<td>No</td>
<td>No</td>
<td>10.1</td>
<td>7</td>
<td>12</td>
</tr>
<tr>
<td>29 (c.1934delG, c.862+1G&gt;T)</td>
<td>&lt;3</td>
<td>&lt;3</td>
<td>5</td>
<td>Yes</td>
<td>Normal</td>
<td>UA</td>
<td>UA</td>
<td>4</td>
<td></td>
<td>10.75</td>
<td>4</td>
</tr>
<tr>
<td>30 (c.1132G&gt;T)</td>
<td>10–25</td>
<td>&lt;3</td>
<td>5</td>
<td>No</td>
<td>Normal</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td></td>
<td>10</td>
<td>16</td>
</tr>
<tr>
<td>38 (c.1096+1G&gt;A)</td>
<td>&lt;3</td>
<td>&lt;3</td>
<td>5</td>
<td>Yes</td>
<td>Mild delay</td>
<td>Normal</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>10.75</td>
<td>14</td>
</tr>
<tr>
<td>39 (c.1402G&gt;C, c.2114C&gt;T)</td>
<td>10–25†</td>
<td>10</td>
<td>5</td>
<td>No</td>
<td>Normal</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>15</td>
<td>33</td>
</tr>
<tr>
<td>44 (c.1191delG, c.2323C&gt;A)</td>
<td>3–10</td>
<td>3</td>
<td>5</td>
<td>No</td>
<td>Normal</td>
<td>UA</td>
<td>UA</td>
<td>11.9</td>
<td></td>
<td>13</td>
<td>9</td>
</tr>
<tr>
<td>51 (c.2542G&gt;T, c.2459G&gt;A)</td>
<td>25</td>
<td>&lt;3</td>
<td>5</td>
<td>No</td>
<td>Normal</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>12</td>
<td>18</td>
</tr>
<tr>
<td>71 (c.836T&gt;C, c.1000C&gt;T)</td>
<td>&lt;3</td>
<td>3–10</td>
<td>5</td>
<td>No</td>
<td>Normal</td>
<td>Yes</td>
<td>No</td>
<td>10.8</td>
<td></td>
<td>10.8</td>
<td>32</td>
</tr>
<tr>
<td>Survival ≥ 20 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65a (c.836T&gt;C, c.2542G&gt;T)</td>
<td>90</td>
<td>75</td>
<td>1</td>
<td>No</td>
<td>Normal</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td></td>
<td>26.9</td>
<td>48</td>
</tr>
<tr>
<td>27 (c.1940A&gt;C)</td>
<td>&lt;3</td>
<td>3–10</td>
<td>2</td>
<td>Yes</td>
<td>Mild delay</td>
<td>Normal</td>
<td>No</td>
<td>No</td>
<td>25.6</td>
<td>37</td>
<td>15</td>
</tr>
<tr>
<td>45 (c.1874C&gt;G, c.2459G&gt;A)</td>
<td>&lt;3</td>
<td>25</td>
<td>2</td>
<td>No</td>
<td>Normal</td>
<td>UA</td>
<td>UA</td>
<td>28.1</td>
<td></td>
<td>20</td>
<td>13</td>
</tr>
<tr>
<td>65b (c.836T&gt;C, c.2542G&gt;T)</td>
<td>25</td>
<td>25</td>
<td>3</td>
<td>No</td>
<td>Normal</td>
<td>Yes</td>
<td>No</td>
<td>24</td>
<td></td>
<td>21</td>
<td>18</td>
</tr>
<tr>
<td>16 (c.1641T&gt;A, c.1933C&gt;T)</td>
<td>&lt;3</td>
<td>3</td>
<td>No</td>
<td>No</td>
<td>Normal</td>
<td>No</td>
<td>No</td>
<td>32</td>
<td></td>
<td>32</td>
<td>13</td>
</tr>
<tr>
<td>57 (c.355C&gt;T)</td>
<td>3–10</td>
<td>3–10</td>
<td>4</td>
<td>Yes</td>
<td>Mild delay</td>
<td>Moderate</td>
<td>No</td>
<td>No</td>
<td></td>
<td>25.9</td>
<td>33</td>
</tr>
<tr>
<td>84 (c.1248_1249insC, c.2104T&gt;G)</td>
<td>&lt;3†</td>
<td>&lt;3</td>
<td>5</td>
<td>No</td>
<td>Normal</td>
<td>Yes†</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
<td>23</td>
<td>33</td>
</tr>
</tbody>
</table>

* Point system reflecting the severity of symptoms associated with SIOD: linear growth failure before 10 years of age received 1 point; renal failure received 1 point; lymphopenia received 1 point; recurrent infections received 1 point; cerebral ischemia received 1 point (19).
† Patient had severe stroke prior to beginning school and was never able to attend mainstream schools.
‡ One generalized seizure at 3 years, apparently unrelated to cerebral ischemic events.
§ One generalized seizure at 13 years, apparently unrelated to cerebral ischemic events.
¶ N/A, not applicable; OFC, occipital-frontal circumference; SIOD, Schimke immuno-osseous dysplasia; UA, unavailable.
hypothesized that SMARCAL1 would be expressed in the mouse and human nervous system and profiled its expression in the developing and mature mouse and human CNS. In the mammalian brain, the Layer I Cajal-Retzius neurons are the first neurons to mature. Other cortical neurons are generated from neural stem cells in the neuroectoderm surrounding the ventricles, that is, the ventricular zone (VZ) and subventricular zone (SVZ), and migrate to form the cortex. Astrocytes and oligodendrocytes also arise from the stem cells in the VZ and SVZ. As the brain matures, the VZ and SVZ retain a small number of neural precursors (21).

As each cell type migrates away from the VZ and SVZ, it differentiates, and this maturation can be detected by expression of specific proteins. The markers followed were as follows: 1) Musashi1 and Nestin, which are markers of neural precursors, immature neurons, and immature astrocytes (18, 22–24); 2) Hu, which is a marker of postmitotic immature and mature neurons (25); 3) GFAP, which is a marker of immature and mature astrocytes (26); and 4) O4 and 2′,3′- cyclic-nucleotide 3′-phosphodiesterase, which are markers of immature and mature oligodendroglia (27, 28).

As assessed by Northern (Fig. 2A) and Western (Fig. 2B) blots, in situ hybridization (Figs. 2C–L), and immunohistochemistry (Figs. 2M–P), we demonstrated that Smarcal1 is expressed in the developing and mature mouse brain. In the embryo, Smarcal1 was strongly expressed in the VZ, SVZ, intermediate zone, and cortical plate (data not shown). In postnatal brains, we observed Smarcal1 expression in the VZ and SVZ, as well as in cortical, cerebellar, spinal, and peripheral neurons (Figs. 2C–P).

By immunofluorescent colocalization studies in the adult mouse brain, we observed cortical colocalization of Smarcal1 with the neuronal marker Hu in postmitotic neurons (Figs. 3A–D), but not with GFAP in mature astrocytes (Figs. 3E–H). In the ependyma and the VZ and SVZ, Smarcal1 colocalized with the precursor cell marker Musashi1 (Figs. 3I–L) and with GFAP in a few SVZ cells (data not shown). We also confirmed expression of Smarcal1 in cultured mouse neural precursors by immunofluorescence (Figs. 3M–R) and Western blot (Fig. 3S) analyses of mouse neurospheres.

We next determined the cell type-specific temporal and spatial distribution of SMARCAL1 in the human brain by Western blot analysis (Figs. 4A, B) and by immunohistochemistry (Figs. 4C–I). We performed immunohistochemistry on 40 human brains ranging in age from 10 GW to 61

FIGURE 1. Analysis of SIOD patient head circumferences. (A) Comparison of head circumference to disease severity. (B) Comparison of head circumference to age of death. (C) Comparison of head circumference to stature. (D) Comparison of head circumference to predicted SMARCAL1 mutation. M, a sequence variant encoding a missense mutation; N, a sequence variant encoding a nonsense, frameshift, or deletion mutation.
In prenatal brains, there was strong nuclear expression of SMARCAL1 in most cells of the immature cortex, in some cells within VZ and SVZ, and along the migratory pathway from the VZ/SVZ to the cortex (Fig. 4C).

Among the 17 postnatal brains (newborn to 61 years old), SMARCAL1 was expressed in the nuclei of a subset of cells in the SVZ and in a subset of cortical neurons (Figs. 4D–F). Expression in cells in the white matter decreased with age (data not shown). SMARCAL1 continued to be expressed predominantly in the nuclei of cortical neurons in the postnatal brains (Figs. 4D–F), although at a lower staining intensity than in the fetal brain. Expression in human neural precursors was confirmed by immunofluorescent (Fig. 4J–L) and reverse-transcriptase-PCR (Fig. 4M) analyses of cultured human neurospheres.

**Neuropathology of SIOD Patients**

The clinical observations of frequent small head circumference and EEG abnormalities in SIOD patients and the
expression of SMARCAL1 during brain development suggest that deficiency of SMARCAL1 may cause defective neurodevelopment. To investigate this possibility, we examined available microscopic sections of brain tissue on Patient SD60, who died of cardiopulmonary arrest at the age of 13 years (10), and Patient SD84, who died of pulmonary hypertension and right heart failure at the age of 23 years (21). Both had had a head circumference of less than the third percentile and normal language, social, motor, and cognitive development. They had excelled academically, as is usual for SIOD patients prior to the onset of cerebral ischemic attacks, and they did not have a seizure disorder. The neuropathologic examination in these cases is regrettably incomplete. Vascular pathology was observed and was previously reported based on our initial observations of several microscopic slides that were available from autopsy material (10). Upon request, additional microscopic slides and some paraffin blocks were kindly sent to us by referring institutions; however, not all regions were sampled or identified. Despite these limitations, we studied the available materials and report our interpretations for comparison to more complete analyses.

Because of the limited samples available, the following observations cannot be considered conclusive or complete. Rather, they are to serve as a basis for future studies. According to the autopsy reports, the brains of Patients SD60 and SD84 weighed less than normal and had areas of infarction and ischemia (Table 2). Despite normal CNS function and antemortem brain magnetic resonance imaging, the nonischemic areas of both brains had very subtle, but consistent, histologic abnormalities. In several focal regions of cerebellar folia, the Purkinje cells (as defined by serial sectioning) seemed to be poorly aligned (Supplemental Fig. 2A); however, because of incomplete materials, the vermis, which has been reported as abnormal by magnetic resonance imaging in some SIOD patients (29), could not be assessed. In the cerebral cortex and the subcortical white matter, focal structural anomalies were observed in 50% of the available cortical sections. The microscopic

![Image of immunofluorescent characterization of Smarcal1 expression in an adult mouse brain. Smarcal1 colocalizes with Hu (A–D) but not with glial fibrillary acidic protein (E–H) in the cortex, and with Musashi1 in the ventricular zone and subventricular zone (I–L). As detected by immunofluorescence (M–R) and Western blot (S), Smarcal1 is also expressed in cultured neurospheres (M–O) and in the individual cells dissociated from the neurospheres (P–R). The negative control for the Western blot is an extract from lymphoblastoid cells from a patient homozygous for deletion of the SMARCAL1 gene promoter and first 4 exons. Bar = 50 μm. cnt, control; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.](image)
malformations included subcortical “heterotopias,” some of which were verified by serial sectioning to be separate from the cortex and not related to tangential sectioning (Supplemental Fig. 2B). Upon serial sectioning, some of the heterotopias (Supplemental Fig. 2B; marked with a star) represented an extension of the expanded cortex as described in the succeeding sentences. Within these areas, no organization of neurons could be discerned. There were also isolated sections of expanded cortex. For example, the cortical thickness in temporal cortex of SD84 ranged from 2.0 to 6.0 mm, whereas in an age-matched control, the same regions measured 1.5 to 4.5 mm. In the “thicker” regions of cortex, there were usually several other associated findings. There was a loss of a well-defined Layer II in each section examined (Supplemental Fig. 2C) as defined by calbindin immunoreactivity, which is normally present in only Layer II neurons (control frontal cortex; Supplemental Fig. 2D). There was poor definition of the cortical gray-white matter junction similar to that observed in cortical dysplasia. In addition, near the expanded cortex, serial sections frequently revealed a failure of separation of gyri and aberrant definition of sulci (data not shown). Importantly, the malformations were

FIGURE 4. Western blot and immunohistochemical analyses of SMARCAL1 protein expression in the human brain. (A) Western analysis for SMARCAL1 expression in protein extracts from whole human brain at 6, 8, and 10 gestational weeks (GW); the brain is predominantly neural precursors at 6 weeks of gestation. The membrane was concurrently probed for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression to control for protein integrity and loading. (B) Western analysis for SMARCAL1 expression in protein extracts from the cortex (cx), cerebellum (cb), and hippocampus (hp) of the adult human brain. The membrane was concurrently probed for GAPDH expression to control for protein integrity and loading. (C) SMARCAL1 expression in the cerebrum of a human 10-GW brain. Cells in the ventricular zone (VZ), subventricular zone (SVZ), IMZ, and the CP express SMARCAL1. Higher-magnification image of SMARCAL1 expression in the CP of the human 10-GW brain (upper inset). Higher-magnification image of SMARCAL1 expression in the VZ and SVZ of the human 10-GW brain (lower inset). (D, E) Expression of SMARCAL1 in the cortex and ependyma of a 40-GW brain. The inset (D) shows SMARCAL1 expression in cortical Layer II. (F) Expression of SMARCAL1 in adult cortical neurons. The inset shows SMARCAL1 expression in cortical Layer II. (G–I) Serial sections treated with preimmune serum. As detected by immunofluorescence (J–L) and reverse-transcriptase-polymerase chain reaction (M), SMARCAL1 is also expressed in cultured neurospheres. Bar = 50 μm. cnt, control; CP, cortical plate; IMZ, intermediate zone; V, ventricle.
TABLE 2. Summary of Brain Pathologic Findings in SIOD Patients SD60 and SD84

<table>
<thead>
<tr>
<th></th>
<th>SD60</th>
<th>SD84</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross pathology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain weight</td>
<td>1,100 g (normal, 1,300 g)</td>
<td>1,020 g (normal, 1,300–1,400 g)</td>
</tr>
<tr>
<td>Blood vessels*</td>
<td>Abnormal</td>
<td>Abnormal</td>
</tr>
<tr>
<td>Cerebrum</td>
<td>Normal gross structure, diffuse ischemic changes</td>
<td>Normal gross appearance, possible focal Purkinje cell crowding</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>Normal gross appearance, possible focal Purkinje cell crowding</td>
<td>Normal gross appearance, possible focal Purkinje cell crowding</td>
</tr>
<tr>
<td>Brainstem</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>Cortical pathology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Focal cortical expansion</td>
<td>4/9†</td>
<td>10/24†</td>
</tr>
<tr>
<td>Subcortical heterotopia</td>
<td>1/9†</td>
<td>4/24†</td>
</tr>
<tr>
<td>Incomplete sulcation</td>
<td>3/9†</td>
<td>5/24†</td>
</tr>
<tr>
<td>Displaced Layer II</td>
<td>2/2†</td>
<td>3/3†</td>
</tr>
</tbody>
</table>

*, The blood vessel pathology is described in Reference 10. †, The denominator is the number of cortical sections available, and the numerator is the number of these sections with the observed alteration. ‡, The denominator is the number of cortical sections stained with anti-calbindin, and the numerator is the number of these sections with the abnormal localization of calbindin-positive neurons.

SIOD, Schimke immuno-osseous dysplasia.

microscopic and required serial sectioning to assess their positions within the cortex. Probably only a powerful and detailed imaging system could have identified them in the living patient.

Because of the role of SMARCAL1 in cell proliferation and its presence in neural precursor cells (and because of the findings in the SIOD cases), we questioned whether neural precursor cells can be identified in subventricular regions in the brain tissue samples. Using the markers Mushashi-1 and Nestin (30), we detected neural precursor cells, indicating that there was not a complete absence of these neural precursor cells in these small brains (Supplemental Figs. 3A–L). There were, however, fewer of them than in the control brain sample (Supplemental Fig. 3P).

Knockdown Studies in Mouse Neurospheres

Based on the suggestion that deficiency of SMARCAL1 contributes to a reduced number of precursors, we performed siRNA knockdown of Smarcal1 in mouse neurospheres. The results indicated that the neurospheres grow less well when they were made deficient in Smarcal1 (Supplemental Figs. 3Q–U). Using 2 different siRNA oligonucleotides for Smarcal1 neurospheres derived from ICR and 129 SvEv mice, 3 independent experiments for each condition showed 53% to 67% transfection efficiency and, as measured by Western blot, a 40% to 50% knockdown of SMARCAL1 protein 4 days after transfection (Supplemental Fig. 3V). Four days after transfection with the Smarcal1 siRNA, the number and radii of neurospheres as well as the number of cells per neurosphere were significantly reduced (p < 0.001), whereas cells transfected with the control siRNA were unaffected (Supplemental Figs. 3Q–U). Therefore, although deficiency for SMARCAL1 does not cause a complete loss of neural precursors, it may be one factor contributing to the small brain size in these patients. These results require confirmation both when there are additional studies on SIOD patient tissues and when Smarcal1 knockout mice become available.

DISCUSSION

SMARCAL1 is a unique member of the SNF2 family of chromatin remodeling proteins that have DNA-dependent adenosine triphosphatase activity (12, 31). We recently determined that mutations of SMARCAL1 cause SIOD (9). In this report, we show for the first time that 1) there is expression of SMARCAL1 in CNS neurons and neural precursors in both humans and mice; 2) SIOD patients often have a reduced head circumference (microcephaly); and 3) autopsy observations of 2 male SIOD patients identify subtle histologic features suggestive of perturbed neuron-glial migration that warrant confirmation and detailed examination in future autopsy studies of SIOD.

The microcephaly is consistent with our previous hypothesis that SMARCAL1 expression facilitates cellular proliferation (9, 10, 19). The head circumference measurements were obtained at birth or prior to the onset of cerebral ischemia, which contributes to reduced brain weight and the acquired cerebellar atrophy reported in some SIOD patients (29). Surprisingly, the microcephaly did not correlate with other clinical features, and despite microcephaly and the subtle histologic features suggestive of perturbed neuron-glial migration, most SIOD patients had generally normal social, language, motor, and cognitive development, and very few had seizures (Table 1). These observations suggest that SMARCAL1 participates in the modulation of both neural proliferation and differentiation but that the morphologic abnormalities that result from deficiency of SMARCAL1 rarely cause serious neurophysiologic dysfunction or developmental deficits. Examination of the brains from SIOD patients who manifest abnormal development or seizures would, however, clarify the range of CNS abnormalities associated with SMARCAL1 deficiency.
The lack of overt functional CNS deficits in most SIOD patients contrasts with the severe neurologic deficits observed with deficiency of the SNF2 factor α-thalassemia mental retardation, X-linked syndrome (32). Individuals with primary microcephaly may, however, have minimal neurologic problems (33–35). Unlike many other skeletal dysplasias and genetic disorders of generalized growth, the relationship between stature and head circumference is not uniform in SIOD. This suggests that loss of SMARCAL1 function is not sufficient for the development of microcephaly, and that stochastic, epigenetic, environmental, or other genetic factors might also contribute to the microcephaly in SIOD patients.

Poor brain growth can result from a reduction in cell number or size but generally has been ascribed to a reduction in cell number (36). Such a reduction can arise either from reduced proliferation or from increased death of glia and/or neurons (37). Based on the spatio-temporal expression of SMARCAL1/Smarcal1 in the human brain, SMARCAL1 deficiency might affect neural precursor viability from early in embryogenesis to postnatal life, thereby contributing to the decreased mean prenatal and postnatal head circumference observed in many of the patients with SIOD. Moreover, the early-onset cognitive impairment that we have observed in some adult SIOD patients might be attributable to a failure of ongoing neurogenesis in addition to the cerebrovascular disease that results in stroke-like episodes (10, 29, 38, 39).

In addition to the modulation of numbers of neural precursor cells, our findings also implicate SMARCAL1 in the regulation of neuronal migration and cortical differentiation. The presence of microscopic periventricular heterotopia, cortical microdysgenesis, and aberrant gyration seen in both autopsy cases have been observed in other disorders of neural migration and cortical patterning (40). Cortical microdysgenesis has been associated with infantile spasms (41), primary generalized epilepsy (42), partial epilepsy (43), dyslexia (44, 45), congenital mental retardation (46), and autism-like disorders (46). Although neither of the autopsy cases we studied was associated with these disorders, histories of the clinical cohort did reveal some of these conditions: 2 SIOD patients had seizures, 7 had EEG changes, and there was mild mental delay in 7. These clinical features in SIOD patients warrant careful examination for evidence of histologic correlates that may suggest perturbed neuron-glial migration. It might also be worth considering whether SIOD patients, who have generally intractable migraine-like headaches, might also be manifesting a partial seizure disorder (16, 47).

The histologic features suggestive of perturbed neuron-glial migration identified would arise from a disturbance in the later stages of radial neuronal migration and cortical organization, whereas heterotopias would arise as a disturbance of the earlier stages of radial neuronal migration. The molecular basis of the cortical microdysgenesis in neurologic disorders is undefined, although some have suggested aberrant secretion of reelin by Cajal-Retzius neurons (48). We found expression of SMARCAL1 in the migrating neuronal precursors, cortical neurons, and in the Cajal-Retzius neurons, but not in cortical oligodendrocytes or astrocytes (Fig. 5). Based on our prior studies suggesting a cell-autonomous function for SMARCAL1 (10, 49, 50), we

![FIGURE 5. Schematic of SMARCAL1/Smarcal1 expression during brain development. (A) In normal developing brain, SMARCAL1 is present in cells of neuronal lineage, including neural precursor cells, migrating immature neurons, and postmigrating neurons in cortex. (B) SMARCAL1 expression remains both in the adult neural stem cells in ventricular zone/subventricular zone and mature cortical neurons. (C) When SMARCAL1 is deficient, the brain is smaller than normal, possibly because the numbers of adult stem cells may be reduced. Potential impairment in neuronal migration and cortical differentiation can result in histologic features suggestive of lesions such as microdysgenesis and abnormal cortical layering.](https://example.com/figure5)
hypothesize that the cortical malformations can arise as a consequence of SMARCAL1 dysfunction within the neuronal lineage.

As a member of the swi/swf class of enzymes, SMARCAL1 might alter chromatin structure and/or expression of genes necessary for neural precursor viability or proliferation as well as for effective neuronal migration. Involvement of chromatin remodeling factors in neural precursor renewal has been observed for the mammalian Polycam group enzyme Bmi-1 (51, 52) and for the Brm-/Brig-1-associated complexes (53–55). Brm-/Brg-1-associated complexes also modulate glial and neuronal differentiation. The murine SWI/SNF (BAF) subunits have nonredundant and dosage-sensitive roles in neural development. Indeed, mice heterozygous for either Brg or BAF155/Srg3 are predisposed to exencephaly (54, 55), and Brg is essential for the repression of neuronal commitment in neural stem cells (56). Furthermore, the transition from proliferating stem/progenitor cells to postmitotic neurons requires a switch in subunit composition of the Brm-/Brg-1-associated complexes (53). We postulate that SMARCAL1/Smarcal1 might be a member of other chromatin remodeling complexes that similarly regulate the expression of genes necessary for neural precursor viability and/or renewal as well as for neuronal migration and cortical differentiation. Thus, deficiency of SMARCAL1 would result in a paucity of neural precursors, abnormalities of neuronal migration, and cortical malformations.

A role for SMARCAL1/Smarcal1 in modulating precursor cell renewal and differentiation can also explain the hematopoiesis defects observed in some SIOD patients (9, 10). If SMARCAL1 promotes viability by inhibiting apoptosis of bone marrow stem cells and influences their differentiation along various lineages, this might explain the stem cell factor-resistant bone marrow failure and the high prevalence of T-cell immunodeficiency among SIOD patients (9).

In summary, we have shown for the first time that the disruption of SMARCAL1 expression in patients with SIOD can result in a small brain size, minimal cortical dysgenesis, and other subtle histologic features suggestive of perturbed neuron-glial migration that are often not detected by clinical and magnetic resonance imaging studies. In view of its similarity to other chromatin remodeling proteins, we propose that SMARCAL1 might act as a chromatin chaperone and thereby modulate the expression of a subset of genes involved in neural development.

ACKNOWLEDGMENTS

The authors thank Gabriella D’Arcangelo, Cecilia Ljungberg, Paolo Moretti, R. Grace Zhai, and Millan Patel for critical review of this article; Gabriella D’Arcangelo for advice and support; Barbara A. Antalfy and Pauline Grennan for preparation of tissue; Kyoung Sang Cho for help with confocal microscopy; Monica J. Justice and Darlene Skapura for mouse tissue; Cecilia Ljungberg for technical assistance in setting up the mouse neural stem cell cultures; and the Birth Defects Laboratory at the University of Washington for human brain tissue.

REFERENCES


© 2008 American Association of Neuropathologists, Inc.